Nabriva Therapeutics AG (NBRV) Cut to “Sell” at Zacks Investment Research
Nabriva Therapeutics AG (NASDAQ:NBRV) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Wednesday, July 12th.
According to Zacks, “Nabriva Therapeutics AG is a biopharmaceutical company. The Company is involved in the research and development of novel anti-infective agents to treat serious infections, which focus on the pleuromutilin class of antibiotics. Its product candidate consists of BC-3781, developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria; BC-7013, a topical pleuromutilin antibiotic which are in different clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria. “
Several other equities research analysts have also recently weighed in on the company. Needham & Company LLC restated a “buy” rating and set a $15.00 target price on shares of Nabriva Therapeutics AG in a report on Monday, March 27th. Cantor Fitzgerald restated a “buy” rating and set a $16.00 target price on shares of Nabriva Therapeutics AG in a report on Tuesday, April 11th. HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of Nabriva Therapeutics AG in a report on Friday, June 30th. ValuEngine upgraded Nabriva Therapeutics AG from a “sell” rating to a “hold” rating in a report on Saturday, June 24th. Finally, Wedbush reiterated an “outperform” rating and issued a $13.00 price objective on shares of Nabriva Therapeutics AG in a report on Monday, May 15th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $15.43.
Shares of Nabriva Therapeutics AG (NBRV) opened at 9.90 on Wednesday. The company’s market capitalization is $26.94 million. Nabriva Therapeutics AG has a one year low of $3.52 and a one year high of $12.75. The firm’s 50-day moving average price is $10.26 and its 200 day moving average price is $10.28.
In other news, Director George Harrison Talbot sold 325 shares of the stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $100.56, for a total value of $32,682.00. Following the completion of the transaction, the director now owns 3,854 shares of the company’s stock, valued at approximately $387,558.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Hbm Healthcare Investments (Ca sold 44,231 shares of the stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $10.50, for a total value of $464,425.50. Following the completion of the transaction, the insider now directly owns 2,421,367 shares of the company’s stock, valued at approximately $25,424,353.50. The disclosure for this sale can be found here. Insiders sold a total of 205,115 shares of company stock valued at $2,252,057 in the last three months.
A number of hedge funds and other institutional investors have recently bought and sold shares of NBRV. Renaissance Technologies LLC bought a new position in Nabriva Therapeutics AG during the fourth quarter worth $103,000. Almanack Investment Partners LLC. bought a new position in Nabriva Therapeutics AG during the first quarter worth $1,870,000. Nationwide Fund Advisors bought a new position in Nabriva Therapeutics AG during the first quarter worth $2,074,000. Finally, Wellington Management Group LLP raised its position in Nabriva Therapeutics AG by 9.9% in the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock worth $25,830,000 after buying an additional 193,951 shares during the period. 56.65% of the stock is owned by institutional investors.
Nabriva Therapeutics AG Company Profile
Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related stocks with our FREE daily email newsletter.